395 related articles for article (PubMed ID: 23393196)
1. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
2. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
3. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
4. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.
Arulanandam R; Batenchuk C; Angarita FA; Ottolino-Perry K; Cousineau S; Mottashed A; Burgess E; Falls TJ; De Silva N; Tsang J; Howe GA; Bourgeois-Daigneault MC; Conrad DP; Daneshmand M; Breitbach CJ; Kirn DH; Raptis L; Sad S; Atkins H; Huh MS; Diallo JS; Lichty BD; Ilkow CS; Le Boeuf F; Addison CL; McCart JA; Bell JC
Cancer Cell; 2015 Aug; 28(2):210-24. PubMed ID: 26212250
[TBL] [Abstract][Full Text] [Related]
5. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
6. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE; Ilett EJ; Melcher AA
Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
8. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
Liu TC; Hwang T; Park BH; Bell J; Kirn DH
Mol Ther; 2008 Sep; 16(9):1637-42. PubMed ID: 18628758
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Heo J; Breitbach CJ; Moon A; Kim CW; Patt R; Kim MK; Lee YK; Oh SY; Woo HY; Parato K; Rintoul J; Falls T; Hickman T; Rhee BG; Bell JC; Kirn DH; Hwang TH
Mol Ther; 2011 Jun; 19(6):1170-9. PubMed ID: 21427706
[TBL] [Abstract][Full Text] [Related]
10. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.
Gentschev I; Müller M; Adelfinger M; Weibel S; Grummt F; Zimmermann M; Bitzer M; Heisig M; Zhang Q; Yu YA; Chen NG; Stritzker J; Lauer UM; Szalay AA
PLoS One; 2011; 6(7):e22069. PubMed ID: 21779374
[TBL] [Abstract][Full Text] [Related]
11. Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma.
Baril P; Touchefeu Y; Cany J; Cherel Y; Thorne SH; Tran L; Conchon S; Vassaux G
J Gene Med; 2011 Dec; 13(12):692-701. PubMed ID: 22028274
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
[TBL] [Abstract][Full Text] [Related]
13. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
14. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
15. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
16. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.
Angarita FA; Acuna SA; Ottolino-Perry K; Zerhouni S; McCart JA
Trends Mol Med; 2013 Jun; 19(6):378-92. PubMed ID: 23540715
[TBL] [Abstract][Full Text] [Related]
17. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
18. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.
Buckel L; Advani SJ; Frentzen A; Zhang Q; Yu YA; Chen NG; Ehrig K; Stritzker J; Mundt AJ; Szalay AA
Int J Cancer; 2013 Dec; 133(12):2989-99. PubMed ID: 23729266
[TBL] [Abstract][Full Text] [Related]
19. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
20. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
